“…B cells from different developmental stages, e.g., developing bone marrow B cells (36), B cells leaving GC structures (33), and medullary plasmablasts leaving lymph nodes (34), have been found to express high levels of surface CXCR4 but were unresponsive to CXCL12. In this regard, there is some evidence that CXCR4 might fulfill additional functions besides chemotaxis, e.g., cell growth, proliferation, and transcriptional activation (11,33,37,38). In accordance, CXCL12 treatment has been found to increase NF-B activity in nuclear extracts from CXCR4-transfected murine pre-B lymphoma cells (37).…”